REGENXBIO building Maryland AAV plant to support gene therapies

Dan Stanton, Managing editor

May 22, 2019

2 Min Read
REGENXBIO building Maryland AAV plant to support gene therapies
Image: iStock/BonneChance

REGENXBIO will construct a GMP facility in Maryland to produce adeno-associated viral vectors for its gene therapy programs using its NAV technology-based platform.

The good manufacturing practice (GMP) plant will be integrated into REGENXBIO’s 132,000 square-foot headquarters in Rockville, Maryland, currently under construction. Financial details have not been disclosed but the manufacturing plant is expected to be operational in 2021.

“The creation of this additional manufacturing capacity using our platform suspension cell culture process will allow us to more efficiently advance our development programs from research stage to the clinic and ultimately to patients, while ensuring manufacturing capacity availability,” chief technology officer Curran Simpson said in a statement.


Image: iStock/BonneChance

The plant will support the firm’s multiple gene-therapy programs through the production of REGENXBIO’s NAV Technology-based vectors at scales up to 2,000 liters.

“REGENXBIO’s novel and unique approach to gene therapy focuses on enabling cells in the body to produce therapeutic proteins or antibodies and targeting and correcting genetic defects,” Kenneth Mills, CEO of REGENXBIO, said earlier this month during a financial conference call.

“Our NAV Technology serves as a backbone gene therapy research and is widely utilized gene therapy platform across diverse disease applications.”

The technology consists of over 100 adeno-associated viral (AAV) vectors including AAV7, AAV8, AAV9 and AAVrh10, which deliver engineered genes to cells. It has so far been used to treat over 200 patients in clinical trials for REGENXBIO and its licensee partners.

The firm has also recently produced its first GMP pulp drug substance based on a new suspension cell culture platform process. “This bioreactor based process enables us to reach manufacturing scale suitable for future commercial production,” chief medical officer Steve Pakola added on the call.

REGENXBIO has several gene therapy candidates in early-phase clinical trials, including RGX-314 for wet AMD, RGX-111 for Mucopolysaccharidosis Type I (MPS I), RGX-121 for Mucopolysaccharidosis Type II (MPS II), and RGX-501 for homozygous familial hypercholesterolemia (HoFH).

REGENXBIO did not respond to comment requests from this publication when contacted by email.

About the Author(s)

Dan Stanton

Managing editor

Journalist covering the international biopharmaceutical manufacturing and processing industries.

Founder and editor of Bioprocess Insider, a daily news offshoot of publication Bioprocess International, with expertise in the pharmaceutical and healthcare sectors, in particular, the following niches: CROs, CDMOs, M&A, IPOs, biotech, bioprocessing methods and equipment, drug delivery, regulatory affairs and business development.

From London, UK originally but currently based in Montpellier, France through a round-a-bout adventure that has seen me live and work in Leeds (UK), London, New Zealand, and China.

You May Also Like